Another very interesting thing about the cc is wha

Another very interesting thing about the cc is what I did not hear - with all of the talk about uplisting, there was no mention by NP of a stock price requirement. I am starting to think that Nasdaq and/or NYSE is so anxious to have Cytodyn uplisted with them that one or more exceptions to the usual listing requirements will be made to accommodate our situation.